Drug Database
PY

pyridoxine oxoglurase (PAK / Glutarase)

✓ Approved

Menarini Group · 小分子 · 小分子

什么是 pyridoxine oxoglurase?

pyridoxine oxoglurase 是一种小分子,由Menarini Group研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名PAK, Glutarase
公司Menarini Group
药物类别小分子
给药途径Unknown
状态Approved

治疗适应症

pyridoxine oxoglurase 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersHepatic encephalopathy✓ Approved
Hepatobiliary disordersHepatic function abnormal✓ Approved
Metabolism and nutrition disordersHyperammonaemia✓ Approved

相关研究文献

PubMedAnnals of medicine and surgery (2012)2026-11-12

Advances in the prevention and management of postoperative nausea and vomiting: a narrative review of pharmacological and integrative approaches.

Abedeen Zain Ul ZU, Ullah Zia Z, Shehzad Namra N, Ahmed Awais A et al.

Postoperative nausea and vomiting (PONV) remain a major complication following surgery. Despite the availability of numerous therapies and international guidelines, it affects approximately 25-30% of patients, with rates reaching 80% among high-risk patients. There are currently no effective measures to completely eliminate the risk of PONV partly because of varying guidelines, the high cost of preventive approaches, and inconsistencies in their use across different clinical settings. Therefore, this narrative review aimed to synthesize the most up-to-date evidence on the prevention and management of PONV. A literature review was performed using MEDLINE and Google Scholar from January 2020 to July 2025 and included meta-analyses, RCTs, and systematic and narrative reviews published after the 2020 guidelines on the management of PONV. Current evidence supports an individualized and multimodal approach to the prevention of PONV, based on artificial intelligence (AI)-assisted risk stratification using the Apfel and Koivuranta scores. In addition, evidence from the literature includes several new pharmacological agents that can be used as adjuncts to established therapies. These include NK-1 antagonists, long-acting 5-HT3 antagonists, and repurposed medications such as midazolam, olanzapine, mirtazapine, and pyridoxine. Evidence regarding integrative approaches, including acustimulation, acupuncture, music, and gum therapy, is promising and appears to be cost-effective. Therefore, the use of individualized multimodal PONV management that combines pharmacological and non-pharmacological strategies will improve the overall prevention of PONV and patient satisfaction. There is a need for further studies of the relationship between pharmacogenomics, AI-assisted risk prediction, and the cost-effectiveness of PONV management in various health care settings.

PMID 43017670
阅读全文 →
PubMedJIMD reports2026-11-11

Spontaneous Coronary Artery Dissection in Pyridoxine-Responsive Classical Homocystinuria: Expanding the Arterial Phenotype.

McCarron Eamon P EP

PMID 43011212
阅读全文 →
PubMedThe Pediatric infectious disease journal2026-11-10

Pyridoxine-responsive Seizures During Isoniazid Preventive Therapy in a Breastfed Infant.

Özbay Yeşfa Şebnem YŞ, Erol Mavera Uşaklioğlu MU, Aslan Zeynep Selen ZS

PMID 43004534
阅读全文 →
PubMedMicrobiome2026-11-05

Gut microbial and metabolic biomarkers for early-onset colorectal cancer.

Nofinska Balqis Arche BA, Mizutani Sayaka S, Salim Felix F, Sunakawa Hironori H et al.

Early-onset colorectal cancer (EO-CRC) is a growing global health challenge with poorly understood etiology. While gut microbiota and metabolites are implicated in colorectal carcinogenesis, EO-CRC-associated signatures remain poorly characterized. This study presents the first large-scale multi-omics analysis in Japan cohort to characterize gut microbial and metabolic features of EO-CRC, with cross-cohort validation in an independent China cohort. We enrolled 510 participants (EO-CRC n = 120, late-onset CRC [LO-CRC] n = 282, young healthy controls [yHC] n = 59, old healthy controls [oHC] n = 49); after age- and sex-matching, 324 samples were analyzed using metagenomics, metabolomics, and quantitative polymerase chain reaction (qPCR). Fourteen species formed a shared CRC-associated microbiome core enriched in both EO-CRC and LO-CRC relative to age-matched controls, of which seven were reproducible across both Japan and China cohorts. Beyond this core, 34 and 21 species were enriched exclusively in EO-CRC and LO-CRC, respectively. Among EO-CRC-specific virulence findings, the bft gene of enterotoxigenic Bacteroides fragilis, fadA of Fusobacterium nucleatum, and bai operon genes were enriched in EO-CRC, with cross-cohort validation for fadA and bai operon, and stage-specific enrichement of deoxycholic acid at Stage 0 providing preliminary metabolomic support. Targeted clbP qPCR revealed enrichment of colibactin-producing Escherichia coli specifically in EO-CRC against a background of age-increasing carriage. Metabolomic profiling identified kynurenine enrichment and depletion of vitamin B-related metabolites (pyridoxine, riboflavin, and nicotinamide) as EO-CRC-specific findings; LO-CRC showed distinct enrichment of carnitine, succinate, and spermine with relative butyrate depletion. The choline degradation pathway was enriched specifically in EO-CRC based on Enteropathway analysis. Species-based random forest classifiers distinguished EO-CRC from controls (AUPRC = 0.828; SD = 0.013; 95% CI 0.739-0.909) and generalized robustly to an independent cohort (AUPRC = 0.817; 95% CI 0.717-0.894), substantially outperforming functional gene profiles in cross-cohort settings. Within the Japan cohort, adding metabolomics provided modest additional discriminative value. These findings identify a shared CRC microbiome core reproducible across age groups and cohorts, alongside EO-CRC-specific signatures encompassing enrichment of virulence-associated genes (bft, fadA), colibactin-producing E. coli (clbP), secondary bile acid biosynthetic genes (bai operon), and choline degradation capacity, as well as distinct metabolic perturbations including kynurenine enrichment and vitamin B-related metabolite depletion. Species-based classifiers generalize well across age groups and cohorts, with metabolomics providing complementary discriminatory value. All findings represent cross-sectional associations; longitudinal studies are needed to establish temporal ordering and evaluate clinical utility as non-invasive biomarkers for EO-CRC. Video Abstract.

PMID 42983896
阅读全文 →
PubMedExperimental neurology2026-11-03

Pyridoxine attenuates Methcathinone-induced cognitive impairment by suppressing ferroptosis via Nrf2/GPX4 pathway.

Xu Chunming C, Zhou Rukui R, Lv Jieping J, Yun Keming K et al.

The precursor of Methcathinone (MeCa) is a cathinone obtained from the plant Catha edulis Forsk. As one of the most prevalent novel psychoactive substances, MeCa has severe neurotoxicology and contributes cognitive dysfunction. Currently, no effective method is available for stopping its progress. Ferroptosis has been proven to contribute to cognitive deficit pathogenesis. Pyridoxine (Pyr) exhibits antioxidative and neuroprotective effects. However, the underlying mechanisms linking Pyr and ferroptosis in MeCa-induced neurotoxicology remain uncertain. The objective of this study is to explore the neuroprotective effects and the potential molecular mechanisms of Pyr against MeCa-induced neurotoxicology in primary hippocampal neurons and male SD rats. In our study, MeCa decreased hippocampal antioxidant capacity, contributed Fe2+ accumulation and mitochondrial dysfunction, induced cognitive impairment and hippocampal neuron injury. Pyr treatment mitigated ferroptosis, alleviated neuronal injury, and attenuated cognitive impairment by activating the Nrf2/GPX4 pathway. Pyr promoted dissociation of Nrf2 and the translocation to the nucleus, and inhibited MeCa-induced Nrf2 ubiquitin degradation. Pyr effectively rescued MeCa-induced cognitive dysfunction by improving neuronal function and synaptic structure, which is related to inhibiting ferroptosis, at least in part, through activating Nrf2/GPX4 axis.

PMID 42977018
阅读全文 →
PubMedFood research international (Ottawa, Ont.)2026-11-01

Hydrothermal degradation mechanism and kinetics of 4'-O-methylpyridoxine and its glucoside in Ginkgo biloba L. seeds.

Kong Yu Y, Wang Yanhua Y, Li Fumin F, Wang Yaping Y et al.

The neurotoxic vitamin B6 derivatives 4'-O-methylpyridoxine (MPN) and 4'-O-methylpyridoxine-5'-glucoside (MPNG) are the primary safety concerns limiting the utilization of nutrient-rich Ginkgo biloba L. seeds (GBSs). In this study, the hydrothermal degradation behavior of MPN and MPNG was systematically investigated. The degradation products were identified as non-toxic pyridoxine (PN), pyridoxine-5'-glucoside (PNG), and methanol using HPLC-IT-TOF-MS, 1H NMR, and GC. Both toxins undergo ether bond cleavage under hydrothermal conditions, a finding further corroborated by ReaxFF molecular dynamics simulations. The degradation follows first-order kinetics with activation energies of 97.5 kJ·mol-1 (MPN) and 96.2 kJ·mol-1 (MPNG), and half-lives of 10.0 and 7.1 min at 180 °C, while PN and PNG exhibit higher thermal stability. Matrix components show starch mildly inhibits MPNG degradation. The mechanism was validated in whole GBSs, confirming hydrothermal processing as an effective detoxification strategy, providing a mechanistic and kinetic framework for optimizing the safe processing of GBS-based food products.

PMID 42967745
阅读全文 →

注册免费账户还可查看另外 6518 篇文献

免费注册查看全部文献 →

了解更多pyridoxine oxoglurase